Impact of Macroeconomics on Profitably of
Baiyunshan
Abstract
Profitability ratios are a class of financial metrics that are used to assess a business's ability to
generate earnings relative to its revenue, operating costs, balance sheet assets, or shareholders'
equity over time, using data from a specific point in time. Profitability ratios are most useful when
compared to similar companies, the company's own history, or average ratios for the company's
industry. We use profitability to analyze the current situation and development prospects of the
pharmaceutical industry
Macro-economic environment
Changes in national policies such as the "4+7" and the approval of innovative drugs, as well as
China-US relations, will have a great impact on the medical industry.
During the epidemic, the demand for public health protection has suddenly increased, and the
equipment used by medical institutions for rescue and life-sustaining will also increase. Products
such as masks must be worn after the outbreak occurs. This may drive the growth of retail
pharmacies of such product terminals, and after the epidemic is over, the growth rate will also drop.
After this epidemic, the people's awareness of self-protection has increased, and a large number of
cold/antiviral drugs will be stockpiled. Therefore, such drugs may increase in a short time.
Business Environment
It is expected that the future may lead to epidemic prevention and control. Hospitals and
grassroots pathogenic microorganisms will gradually increase their molecular diagnostic testing
capabilities, and the demand for related diagnostic products will continue to grow. This may be one
of the few sub-fields with far-reaching influence.
Affected by the illness, the public's awareness of disease prevention will increase in the future.
In the future, the country may increase support for vaccines (pneumonia vaccine, flu vaccine, etc.),
blood products (such as immunoglobulin), and interferon (such as respiratory tract aerosol therapy).
The biomedicine industry in the post-epidemic era has achieved leapfrog development through
the capital market, which contains huge opportunities for the benefit of mankind. Under this
background, how will the ecology of the entire pharmaceutical industry be reshaped? How will the
medical industry follow the trend and take the initiative to seek new breakthroughs by investigating
revenue growth rate?
Now many medicine companies are experiencing fierce market competition. Even though they
have channel and cost advantages, it is difficult for them to survive without innovative differences
in products. And low-cost medical care is the direction that we firmly believe China's medical
services will develop in the future. Pharmaceutical companies who can minimize costs can get the
most profits.
Academician Zhong Nanshan mentioned in the report that since the outbreak of the new crown
pneumonia, the research team and 16 listed Chinese patent medicine systems of 10 companies in
Guangdong have carried out in vitro drug efficacy screening against the new coronavirus, and found
that the compound Banlangen particles and Kouyanqing Granules and other well-known Chinese
patent medicines in Guangdong show varying degrees of in vitro inhibitory effects. "These studies
will inject new impetus into the in-depth research and clinical application of anti-coronavirus